What is MIMs?
MIMs specializes in delivering easy-to-implement and interactive augmented intelligence systems tailored for the pharmaceutical sector. Their core technology enables accurate biological simulations during the early stages of drug development, empowering scientists to design precisely targeted and personalized therapies. Headquartered in Quebec, Canada, MIMs is strategically positioned to support pharmaceutical companies of all sizes in accelerating their research and development pipelines with advanced AI-driven insights.
How much funding has MIMs raised?
MIMs has raised a total of $5M across 1 funding round:
Other Financing Round
$5M
Other Financing Round (2021): $5M with participation from Anges Québec, StandUp Ventures, Medteq, Real Ventures, Desjardins Capital, and Anges Québec Capital
Key Investors in MIMs
Anges Québec
Anges Québec is an angel investor network that supports Quebec-based startups. They focus on providing capital and expertise to early-stage companies.
StandUp Ventures
Stand Up Ventures is a stage venture capital fund focused on investing in high growth ventures. The company was established in 2017 and is based in Toronto, Ontario.
Real Ventures
Real Ventures serves mission-driven entrepreneurs and nurtures the communities in which they thrive. The firm backs visionary founders building innovative tech companies that will have large-scale positive impacts on society.
What's next for MIMs?
With a substantial infusion of capital, MIMs is poised for accelerated growth and market expansion. The company's focus on integrating AI with systems biology for drug discovery suggests a strategic direction towards enhancing the efficiency and accuracy of therapeutic development. Future endeavors will likely involve scaling their augmented intelligence platforms, forging deeper partnerships within the pharmaceutical industry, and further refining their simulation capabilities to address complex biological challenges. This enterprise-level backing signals a strong market validation and provides the resources for MIMs to solidify its position as a key innovator in AI-driven pharmaceutical research.
See full MIMs company page
